Vyne Revenue and Competitors
Estimated Revenue & Valuation
- Vyne's estimated annual revenue is currently $6.4M per year.
- Vyne's estimated revenue per employee is $152,000
- Vyne's total funding is $15.5M.
Employee Data
- Vyne has 42 Employees.
- Vyne grew their employee count by -16% last year.
Vyne's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Co-founder | Reveal Email/Phone |
2 | Chief Revenue Officer (CRO) | Reveal Email/Phone |
3 | Head Customer Success | Reveal Email/Phone |
4 | Head Sales | Reveal Email/Phone |
5 | Finance Director | Reveal Email/Phone |
6 | Director Product | Reveal Email/Phone |
7 | Director Risk and Compliance | Reveal Email/Phone |
8 | Finance Director | Reveal Email/Phone |
9 | Director Engineering | Reveal Email/Phone |
10 | Director Strategy | Reveal Email/Phone |
Vyne Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $55.7M | 241 | -24% | N/A | N/A |
#2 | $12.5M | 66 | -3% | N/A | N/A |
#3 | $3.4M | 23 | 0% | N/A | N/A |
#4 | $16.2M | 77 | 28% | N/A | N/A |
#5 | $48M | 208 | 2% | N/A | N/A |
#6 | $85.1M | 324 | 19% | N/A | N/A |
#7 | $88.2M | 336 | 40% | N/A | N/A |
#8 | $411M | 1398 | 17% | N/A | N/A |
#9 | $105.3M | 401 | 55% | N/A | N/A |
#10 | $105.9M | 397 | 5% | $878.2M | N/A |
What Is Vyne?
vyne provides fast, efficient and secure bank to bank payments for Ecommerce apps and websites.
keywords:N/A$15.5M
Total Funding
42
Number of Employees
$6.4M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vyne News
2022-04-17 - -$0.15 EPS Expected for VYNE Therapeutics Inc. (NASDAQ ...
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
2022-04-17 - Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ ...
Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $550,000.00. Posted by admin on Apr 22nd, 2022.
2022-04-06 - VYNE Therapeutics Announces Positive Phase 1b Efficacy ...
FMX114 is VYNE's proprietary investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.9M | 42 | -5% | N/A |
#2 | $8.4M | 42 | 2% | N/A |
#3 | $11M | 42 | 8% | N/A |
#4 | $8.4M | 42 | 0% | N/A |
#5 | $6.9M | 42 | 31% | N/A |